EGFR mutation + PIK3CA mutation	Lung Adenocarcinoma	EGFR mutation + PIK3CA mutation	Lung Adenocarcinoma	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3
EGFR mutation + PIK3CA mutation	Non Small Cell Lung Cancer	EGFR mutation + PIK3CA mutation	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3
EGFR mutation + PIK3CA mutation	Non Small Cell Lung Cancer	EGFR mutation + PIK3CA mutation	Non Small Cell Lung Cancer	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3
EGFR mutation + PIK3CA mutation	Lung Adenocarcinoma	EGFR mutation + PIK3CA mutation	Lung Adenocarcinoma	aumolertinib Sensitive: C4 – Case Studies aumolertinib Sensitive : C4	aumolertinib Sensitive: C4 – Case Studies aumolertinib Sensitive : C4

EGFR mutation + PIK3CA mutation

Associations